Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SHPMY steht fuer Shanghai Pharmaceuticals Holding Co., Ltd, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 40/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Gesundheitswesen & Pipeline-Uebersicht
Shanghai Pharmaceuticals Holding Co., Ltd., a major player in the Chinese pharmaceutical sector, focuses on the entire value chain from R&D and manufacturing to distribution and retail. With a diverse product portfolio and a wide network of retail pharmacies, it addresses key therapeutic areas while navigating the evolving healthcare landscape in China.
Investmentthese
Shanghai Pharmaceuticals Holding Co., Ltd. presents a compelling investment case based on its integrated business model and strong market position in China. The company's diverse product portfolio and extensive distribution network provide a stable revenue base. With a P/E ratio of 11.36 and a dividend yield of 2.37%, the stock offers potential value and income. Growth catalysts include expanding its retail pharmacy network and increasing its focus on innovative drugs. However, investors may want to evaluate the regulatory risks and competitive pressures in the Chinese pharmaceutical market, as well as the impact of currency fluctuations on its ADR.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $5.64 billion, reflecting its significant presence in the Chinese pharmaceutical market.
- P/E ratio of 11.36, suggesting a potentially undervalued stock compared to its earnings.
- Profit margin of 2.0%, indicating room for improvement in operational efficiency.
- Gross margin of 10.6%, highlighting the need to optimize production and distribution costs.
- Dividend yield of 2.37%, providing a steady income stream for investors.
Wettbewerber & Vergleichsunternehmen
Staerken
- Integrated business model covering R&D, manufacturing, distribution, and retail.
- Extensive distribution network across China.
- Diverse product portfolio catering to various therapeutic areas.
- Established brand reputation in the Chinese pharmaceutical market.
Schwaechen
- Relatively low profit margin compared to global peers.
- Dependence on the Chinese market.
- Exposure to regulatory changes and pricing pressures.
- Limited international presence.
Katalysatoren
- Upcoming: Potential regulatory approvals for new drugs in the pipeline.
- Ongoing: Expansion of the retail pharmacy network across China.
- Ongoing: Increasing demand for pharmaceutical products due to an aging population.
- Ongoing: Growth in the online drug business and e-commerce trends.
Risiken
- Potential: Regulatory changes and pricing pressures in the Chinese pharmaceutical market.
- Potential: Currency fluctuations impacting ADR value.
- Potential: Increasing competition from domestic and international players.
- Ongoing: Supply chain disruptions affecting manufacturing and distribution.
- Ongoing: Dependence on the Chinese market.
Wachstumschancen
- Expansion of Retail Pharmacy Network: Shanghai Pharmaceuticals can grow by expanding its network of retail pharmacies across China. With approximately 2,000 retail chain pharmacies currently, there is potential to increase market share by penetrating underserved regions and offering value-added services like telemedicine and chronic disease management. The Chinese retail pharmacy market is projected to reach $300 billion by 2028, presenting a significant opportunity for growth.
- Development of Innovative Drugs: Investing in research and development to create innovative drugs can drive long-term growth. Focusing on high-demand therapeutic areas like oncology and CNS disorders can lead to higher-margin products and increased market share. The global market for innovative drugs is expected to reach $1.2 trillion by 2030, offering substantial revenue potential.
- Strengthening Distribution Network: Optimizing and expanding its pharmaceutical distribution network can improve efficiency and reach. Investing in advanced logistics and supply chain technologies can reduce costs and enhance service quality. The Chinese pharmaceutical distribution market is expected to grow at a CAGR of 8% over the next five years, driven by increasing demand for pharmaceuticals.
- Online Drug Business Expansion: Growing its online drug business can tap into the increasing trend of online healthcare and e-commerce. Offering a wider range of products and services online, along with convenient delivery options, can attract new customers and increase sales. The online pharmacy market in China is projected to reach $100 billion by 2027, presenting a significant growth opportunity.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies and acquiring smaller players can expand its product portfolio and market reach. Collaborating with international companies can also provide access to new technologies and markets. The pharmaceutical industry is witnessing increasing consolidation, and strategic alliances can enhance competitiveness.
Chancen
- Expanding retail pharmacy network in underserved regions.
- Investing in research and development of innovative drugs.
- Growing online drug business to tap into e-commerce trends.
- Forming strategic partnerships and acquisitions to expand market reach.
Risiken
- Increasing competition from domestic and international players.
- Regulatory changes and pricing pressures affecting profitability.
- Currency fluctuations impacting ADR value.
- Potential supply chain disruptions.
Wettbewerbsvorteile
- Extensive Distribution Network: Its widespread distribution network provides a significant competitive advantage in reaching customers across China.
- Diverse Product Portfolio: A broad range of pharmaceutical products reduces reliance on any single product and caters to various therapeutic areas.
- Established Brand Reputation: A long history and established brand name in the Chinese pharmaceutical market provide trust and recognition.
- Integrated Business Model: Its integrated model, covering R&D, manufacturing, distribution, and retail, provides greater control and efficiency.
Ueber SHPMY
Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China. As an investment holding company and a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., it operates across four segments: Production, Distribution, Retail, and Others. The Production segment focuses on manufacturing a diverse range of pharmaceutical products, including chemicals, biochemicals, Chinese medicines, healthcare products, and medical devices. These products target therapeutic areas such as oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. The Distribution segment provides pharmaceutical distribution, warehousing, and logistics services to manufacturers, hospitals, distributors, and retail pharmacies. The Retail segment operates a network of approximately 2,000 retail chain pharmacies across 24 provinces, along with an online drug business. The company also offers consulting services, asset management, clinical trials, medical aid, physician education, e-prescription management, and remote hospital services. Shanghai Pharmaceuticals Holding Co., Ltd. plays a critical role in the Chinese healthcare ecosystem, providing a comprehensive suite of products and services.
Was das Unternehmen tut
- Researches and develops pharmaceutical products.
- Manufactures a wide range of drugs and healthcare products.
- Distributes pharmaceutical products to hospitals, distributors, and retail pharmacies.
- Operates a network of approximately 2,000 retail chain pharmacies.
- Provides pharmaceutical supply chain solutions and related services.
- Engages in online drug business.
- Offers consulting services and asset management operations.
- Conducts clinical trials and provides medical aid.
Geschaeftsmodell
- Generates revenue from the sale of manufactured pharmaceutical products.
- Earns fees from providing pharmaceutical distribution and logistics services.
- Derives income from retail sales through its pharmacy network.
- Receives revenue from online drug sales.
- Provides consulting and asset management services for additional income.
Branchenkontext
Shanghai Pharmaceuticals Holding Co., Ltd. operates in the rapidly growing Chinese pharmaceutical market. The industry is driven by increasing healthcare spending, an aging population, and rising chronic disease prevalence. The company competes with other major pharmaceutical distributors and manufacturers, including CNVVF (China National Medicines Corporation Ltd), CNVVY (Sinopharm Group Co Ltd), DSRLF (D S Healthcare Holdings Ltd), GNGBY (Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd), and GZPHF (Guangzhou Pharmaceutical Co Ltd). Regulatory changes and pricing pressures pose ongoing challenges, but also create opportunities for companies with strong distribution networks and innovative product pipelines.
Wichtige Kunden
- Hospitals and healthcare institutions.
- Pharmaceutical distributors and wholesalers.
- Retail pharmacies.
- Individual consumers through retail pharmacies and online channels.
- Pharmaceutical manufacturers.
Finanzdaten
Chart & Info
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
-
New 52-Week Lows For Monday Morning
· 5. Aug. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer SHPMY.
Kursziele
Wall-Street-Kurszielanalyse fuer SHPMY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von SHPMY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Qiuhua Yang
Unknown
Information on Qiuhua Yang's background is not available in the provided context. Details regarding their education, previous roles, and career history are unknown. Further research would be needed to provide a comprehensive profile.
Erfolgsbilanz: Information on Qiuhua Yang's track record is not available in the provided context. Specific achievements, strategic decisions, and company milestones under their leadership are unknown. Further research would be needed to assess their performance.
Shanghai Pharmaceuticals Holding Co., Ltd ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) like SHPMY represents shares of a foreign company (Shanghai Pharmaceuticals) held by a U.S. depositary bank. SHPMY allows U.S. investors to trade shares of Shanghai Pharmaceuticals on the OTC market in U.S. dollars, simplifying investment in the Chinese market.
- Heimatmarkt-Ticker: Shanghai Stock Exchange, China
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: SHPM
SHPMY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies on this tier often have limited financial disclosure, may not meet minimum listing standards, and carry higher risks compared to companies listed on exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires extra due diligence due to the lack of regulatory oversight and transparency.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC stocks.
- Consider seeking professional financial advice.
- Monitor trading volume and price movements.
- Subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
- Operations in the highly regulated pharmaceutical industry.
- Presence in the Chinese market since 1994.
- Extensive distribution network and retail pharmacy operations.
Shanghai Pharmaceuticals Holding Co., Ltd Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for SHPMY?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) currently holds an AI score of 40/100, indicating low score. Key strength: Integrated business model covering R&D, manufacturing, distribution, and retail.. Primary risk to monitor: Potential: Regulatory changes and pricing pressures in the Chinese pharmaceutical market.. This is not financial advice.
How frequently does SHPMY data refresh on this page?
SHPMY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SHPMY's recent stock price performance?
Recent price movement in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Integrated business model covering R&D, manufacturing, distribution, and retail.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SHPMY overvalued or undervalued right now?
Determining whether Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SHPMY?
Before investing in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SHPMY to a portfolio?
Potential reasons to consider Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Integrated business model covering R&D, manufacturing, distribution, and retail.. Additionally: Extensive distribution network across China.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of SHPMY?
Yes, most major brokerages offer fractional shares of Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SHPMY's earnings and financial reports?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for SHPMY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market investments carry higher risks than exchange-listed stocks.
- AI analysis is pending and may provide further insights.